

Deborah L White

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9500503/deborah-l-white-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

5,139
citations

28
h-index

71
g-index

131
ext. papers

5,861
ext. citations

5.9
avg, IF

4.96
L-index

#	Paper	IF	Citations
119	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 1005-15	59.2	885
118	BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. <i>Nature</i> , 2008 , 453, 110-4	50.4	835
117	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. <i>Blood</i> , 2013 , 122, 515-22	2.2	519
116	OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. <i>Blood</i> , 2006 , 108, 697-704	2.2	370
115	Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. <i>Blood</i> , 2007 , 110, 4064-72	2.2	277
114	Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. <i>Clinical Cancer Research</i> , 2008 , 14, 3881-8	12.9	157
113	Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2761-7	2.2	153
112	Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. <i>Blood</i> , 2008 , 112, 3965-73	2.2	151
111	CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. <i>Blood</i> , 2017 , 129, 1166-1176	2.2	95
110	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. <i>Haematologica</i> , 2013 , 98, 193-200	6.6	83
109	Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. <i>Blood</i> , 2018 , 132, 948-961	2.2	80
108	Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. <i>Blood</i> , 2014 , 123, 1218-28	2.2	74
107	TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. <i>Blood</i> , 2015 , 125, 915-23	2.2	65
106	Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. <i>Leukemia</i> , 2010 , 24, 765-70	10.7	57
105	Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 294-306	6.1	54
104	Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4445-51	2.2	53
103	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. <i>Haematologica</i> , 2012 , 97, 907-14	6.6	48

102	Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2139-47	1.9	48
101	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. <i>Leukemia</i> , 2010 , 24, 771-8	10.7	45
100	The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. <i>Leukemia</i> , 2017 , 31, 75-82	10.7	44
99	Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 3763-7	5.6	43
98	Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. <i>Blood</i> , 2007 , 109, 3609-10	2.2	43
97	OCT1 and imatinib transport in CML: is it clinically relevant?. <i>Leukemia</i> , 2015 , 29, 1960-9	10.7	41
96	Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. <i>Leukemia</i> , 2003 , 17, 821-8	10.7	39
95	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. <i>Leukemia</i> , 2018 , 32, 2572-2579	10.7	37
94	High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. <i>Haematologica</i> , 2017 , 102, e490-e493	6.6	36
93	OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. <i>Leukemia</i> , 2010 , 24, 1962-5	10.7	36
92	Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms. <i>Human Genetics</i> , 1995 , 95, 641-4	6.3	33
91	Guidelines for whole genome bisulphite sequencing of intact and FFPE DNA on the Illumina HiSeq X Ten. <i>Epigenetics and Chromatin</i> , 2018 , 11, 24	5.8	27
90	Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. <i>Leukemia</i> , 2015 , 29, 76-85	10.7	27
89	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. <i>Leukemia</i> , 2010 , 24, 658-60	10.7	27
88	The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression. <i>Oncotarget</i> , 2018 , 9, 13423-13437	3.3	24
87	Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. <i>Leukemia and Lymphoma</i> , 2013 , 54, 198-201	1.9	23
86	Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. <i>Leukemia</i> , 2020 , 34, 1052-1061	10.7	23
85	Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. <i>British Journal of Haematology</i> , 2020 , 191, 433-441	4.5	22

84	genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2018 , 103, 2026-2032	6.6	22
83	TGF- β and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. <i>Leukemia</i> , 2016 , 30, 1263-72	10.7	21
82	Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. <i>Leukemia and Lymphoma</i> , 2013 , 54, 569-78	1.9	21
81	Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. <i>Leukemia</i> , 2015 , 29, 1792-4	10.7	20
80	Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. <i>Leukemia</i> , 2015 , 29, 230-2	10.7	20
79	Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. <i>Blood Advances</i> , 2019 , 3, 1610-1621	7.8	20
78	A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 185-92	5.1	19
77	ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. <i>PLoS ONE</i> , 2016 , 11, e0161470	3.7	19
76	KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. <i>Blood</i> , 2015 , 126, 2720-3	2.2	18
75	The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. <i>Blood</i> , 2010 , 116, 2776-8	2.2	18
74	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. <i>Cancer Letters</i> , 2017 , 408, 92-101	9.9	17
73	Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. <i>British Journal of Cancer</i> , 2012 , 106, 1772-8	8.7	16
72	Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1144-5; author reply 1145-6	2.2	15
71	Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. <i>British Journal of Cancer</i> , 2018 , 118, 1000-1004	8.7	14
70	Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia. <i>Cancer Research</i> , 2016 , 76, 2766-2777	10.1	14
69	ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. <i>PLoS ONE</i> , 2018 , 13, e0192180	3.7	13
68	Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells. <i>Leukemia</i> , 2009 , 23, 1205-6	10.7	13
67	OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. <i>Haematologica</i> , 2011 , 96, 213-206	20.6	12

66	Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. <i>Haematologica</i> , 2013 , 98, 896-900	6.6	11
65	CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. <i>Blood</i> , 2008 , 112, 3187-3187	2.2	11
64	Low GF11 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation. <i>Leukemia</i> , 2013 , 27, 1427-30	10.7	10
63	Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. <i>Leukemia</i> , 2010 , 24, 855-7	10.7	10
62	KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease. <i>Cancer Letters</i> , 2020 , 469, 410-418	9.9	10
61	NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. <i>Leukemia</i> , 2013 , 27, 489-90	10.7	9
60	OCT-1 as a determinant of response to antileukemic treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 608-11	6.1	9
59	Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. <i>Blood</i> , 2011 , 118, 451-451	2.2	9
58	CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 977-985	6.2	8
57	A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. <i>Cancer Genetics</i> , 2017 , 216-217, 86-90	2.3	8
56	COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016 , 7, 53064-53073	3.3	8
55	Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28922	3	8
54	Increased peroxisome proliferator-activated receptor α activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. <i>Haematologica</i> , 2017 , 102, 843-853	6.6	7
53	Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2019 , 186, e56-e60	4.5	7
52	Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2018 , 32, 2288-2291	10.7	7
51	A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. <i>Journal of Molecular Diagnostics</i> , 2017 , 19, 711-721	5.1	7
50	Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. <i>Leukemia</i> , 2013 , 27, 1201-4	10.7	7
49	Predicting the response of CML patients to tyrosine kinase inhibitor therapy. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 88-95	4.4	7

48	Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish. <i>Pathology</i> , 1997 , 29, 289-93	1.6	7
47	Living with CML: is death no longer the end (point)?. <i>Blood</i> , 2015 , 126, 2-4	2.2	6
46	Predicting the response of CML patients to tyrosine kinase inhibitor therapy. <i>Current Hematologic Malignancy Reports</i> , 2009 , 4, 59-65	4.4	6
45	Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. <i>Blood</i> , 2018 , 132, 459-459	2.3	6
44	Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines. <i>Oncotarget</i> , 2018 , 9, 34735-34747	3.3	6
43	The expression of mature myeloid cell differentiation markers in acute leukemia. <i>Pathology</i> , 1987 , 19, 137-42	1.6	6
42	The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL. <i>British Journal of Cancer</i> , 2020 , 122, 455-464	8.7	6
41	Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. <i>Expert Review of Hematology</i> , 2011 , 4, 285-99	2.8	5
40	Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. <i>Leukemia</i> , 2014 , 28, 702-5	10.7	4
39	DUX Hunting-Clinical Features and Diagnostic Challenges Associated with -Rearranged Leukaemia. <i>Cancers</i> , 2020 , 12,	6.6	4
38	The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota.. <i>Cell Reports Medicine</i> , 2021 , 2, 100464	18	4
37	Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. <i>Cytotherapy</i> , 2003 , 5, 534-41	4.8	3
36	Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. <i>Blood</i> , 2019 , 134, 3904-3904	3.0	3
35	Genome-Wide Analysis of Genetic Alterations in Chronic Myelogenous Leukemia.. <i>Blood</i> , 2008 , 112, 1089-1089	2.1	3
34	Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. <i>Blood</i> , 2008 , 112, 196-196	2.2	3
33	B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification. <i>British Journal of Haematology</i> , 2021 ,	4.5	3
32	MLL10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 709	5	3
31	Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. <i>Cancers</i> , 2020 , 12,	6.6	3

30	Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia. <i>PLoS ONE</i> , 2017 , 12, e0168947	3.7	2
29	The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. <i>Blood</i> , 2015 , 126, 4841-4841	2.2	2
28	ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib. <i>Blood</i> , 2011 , 118, 2745-2745	2.2	2
27	Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia. <i>Cancer Letters</i> , 2021 , 512, 28-37	9.9	2
26	Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients. <i>Cancer Letters</i> , 2018 , 432, 69-74	9.9	1
25	Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. <i>Blood</i> , 2020 , 136, 13-14	2.2	1
24	The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. <i>Blood</i> , 2015 , 126, 348-348	2.2	1
23	A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. <i>Blood</i> , 2015 , 126, 596-596	2.2	1
22	A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. <i>Blood</i> , 2016 , 128, 1121-1121	2.2	1
21	High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse. <i>British Journal of Haematology</i> , 2020 , 191, 301-304	4.5	1
20	Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation. <i>Anti-Cancer Drugs</i> , 2021 , 32, 526-536	2.4	1
19	Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia. <i>Npj Precision Oncology</i> , 2021 , 5, 75	9.8	1
18	Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.. <i>British Journal of Haematology</i> , 2021 ,	4.5	1
17	Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an in Vitro model of a High-Risk Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020 , 136, 5-6	2.2	0
16	Monocytoid switch in an adult with B-cell precursor acute lymphoblastic leukaemia characterised by the PAX5 P80R mutation.. <i>Pathology</i> , 2021 ,	1.6	0
15	Case Report: Precision Medicine Target Revealed by Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis.. <i>Frontiers in Oncology</i> , 2022 , 12, 851572	5.3	0
14	Response to Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics? <i>Leukemia</i> , 2017 , 31, 769-770	10.7	
13	Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?. <i>Leukemia and Lymphoma</i> , 2011 , 52, 165-7	1.9	

12	Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1022-3	1.9
11	Persistent Activation of JAK/STAT Signaling Plays an Important Role in In Vitro JAK2 Resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. <i>Blood</i> , 2020 , 136, 3-3	2.2
10	Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 568-568	2.2
9	High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen. <i>Blood</i> , 2019 , 134, 3949-3949	2.2
8	A Novel Role for HMG1 in Down Syndrome Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019 , 134, 1462-1462.	2.2
7	The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients.. <i>Blood</i> , 2008 , 112, 1109-1109	2.2
6	Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib [A TOPS Correlative Substudy. <i>Blood</i> , 2010 , 116, 670-670	2.2
5	Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy,. <i>Blood</i> , 2011 , 118, 3501-3501	2.2
4	MicroRNA Dysregulation in Newly Diagnosed Chronic Myeloid Leukaemia Patients. <i>Blood</i> , 2013 , 122, 4985-4985	2.2
3	STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner. <i>Blood</i> , 2013 , 122, 2705-2705	2.2
2	modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene - implications for targeted therapy. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1157-1166	1.9
1	CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021 , 193, 171-175	4.5